Can allogeneic red cell transfusions for preterm/very low birth weight newborns be reduced and is this associated with favourable outcome of usual neonatal complications (infections, cerebral bleeding , duration of assisted ventilation and death)…
ID
Bron
Verkorte titel
Aandoening
The study population exists of prematures born after a gastational age of less than 32 weeks and 32-36 weeks with Apgar score <6, for whom at least 1 erythrocyte product is stored. The NICU is informed that this patient is a study candidate. The transfusion indications are decided by the treating physicians according to quidelines from the Dutch Society for Neonatology. In case the first transfusion is indicated the patient is randomly assigned to the autologous or an allogeneic red cell product. A pre and post transfusion Hb is determined. In case more transfusions are needed the patient who was assigned to the autologous transfusion arm receives autologous red cells as long as products are available or up to a period of 3 weeks.
Ondersteuning
Project OOPEP/1044 of Sanquin Blood supply
P.O. box 93245
2509 AE The Hague
070.3495111
info@zonmw.nl
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Proportion of patients who received allogeneic transfusions and the total volume of administered allogeneic red cells.
Days of support of vital functions in the NICU.
Achtergrond van het onderzoek
Bloodsubstitutes are becoming a pivotal medical aim. Efforts to find blood substitutes instead of donor blood are enforced by the awareness that allogeneic blood transfusions, despite optimal safety precautions, can be associated with worse clinical outcome. In addition there is a realistic expectation of decrease in the numbers of safe blood donors in the near future.
Preterm newborns with a gestational age less than 32 weeks and/or 32-36 weeks and Apgar score <6 have a high probability to receive blood transfusions. Preterm newborns also have a high risk for respiratory and other organ failure, septicaemia and cerebral bleeding. In adults, blood transfusions are associated with increased morbidity and mortality. It is conceivable that preterm infants are even more susceptible to the adverse effects of allogeneic transfusions. Neonatal diseases may have life-long sequelae such as chronic lung disease, impaired neurodevelopmental outcome and retinipathy.
- Cordblood (CB) is generally discarded, but contains red cells, immature hematopoietic cells and stem cells suitable for autologous and allogeneic usage. CB red cells can be harvested, stored and transfused without side effects.
In the proposed double-blind randomised study we compare the use of autologous CB red cells with allogeneic transfusions.
- Primary outcome measure is a meaningfull (> 50% reduction) in allogeneic red cell transfusions.
- Secondary parameters are
a. postnatal complication rate (infections, duration of respiratory assistance, intracranial bleeding ,length of ICU-stay)
b. feasibility to obtain autologous CB transfusions on a wide scale
c. costs compared to standard treatment.
Doel van het onderzoek
Can allogeneic red cell transfusions for preterm/very low birth weight newborns be reduced and is this associated with favourable outcome of usual neonatal complications (infections, cerebral bleeding , duration of assisted ventilation and death) resulting in shortening of the need of vital support necessitating NICU care.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
Transfusion of autologous red cord blood cell concentrate vs. transfusion of stored allogeneic red blood cell concentrates.
Algemeen / deelnemers
P.0. Box 2184
A. Brand
Leiden 2301 CD
The Netherlands
+31 (0)71 5685053
Anneke.Brand@bloodrtd.nl
Wetenschappers
P.0. Box 2184
A. Brand
Leiden 2301 CD
The Netherlands
+31 (0)71 5685053
Anneke.Brand@bloodrtd.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Pregnant women;
2. Premature (gestational age of < 36 weeks) who require a red blood cell transfusion.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Hemolytic disease of the newborn;
2. Maternal infections such as HIV/HCV/HBV/CMV/ Toxoplasma/ Treponema pallidum or maternal septicaemia;
3. Ruptured membranes >24 hr and body temp. >38 gr. C;
4. placenta praevia, version, solutio placentae;
5. antibiotics/fungostatica < 48 hr prior to partus.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL219 |
| NTR-old | NTR256 |
| Ander register | : N/A |
| ISRCTN | ISRCTN01566504 |